IL1B and epilepsy: IL-1β is recognized to contribute to epilepsy development124, and the therapeutic effect of the IL-1β antagonist, Anakinra, has been reported in the relapsing chronic phase of febrile infection–related epilepsy syndrome125, as well as in the super-refractory status epilepticus and febrile infection-related epilepsy syndrome126.